Inhibition of rotavirus infection in vitro and in vivo by a synthetic peptide from VP4.
A synthetic peptide corresponding to bovine rotavirus C486 (BRV) VP4 amino acid sequence 232-255 (VP4-peptide) was studied with the objective of defining the origin of the protective immune response reported previously by Ijaz et al. (J. Virol. 1991, 65, 3106-3113). Pretreatment of MA-104 cells with the VP4-peptide before infection with rotavirus prevented both the attachment of 35S-labelled virus and plaque formation in vitro. In vivo studies using a murine rotavirus model demonstrated that intragastric administration of VP4-peptide protected subjects from challenge with virulent rotavirus. These results clearly indicate the importance of this epitope in virus-cell interactions and their potential as a rotavirus vaccine candidate.
Division of Infectious Diseases, H.H. Shaikh Khalifa Research Centre for Racing Camels, Abu-Dhabi, United Arab Emirates.
M K
MK
Ijaz
M S
MS
Nur-E-Kamal
F K
FK
Dar
S
S
Uduman
M J
MJ
Redmond
S K
SK
Attah-Poku
D
D
Dent
L A
LA
Babiuk
D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites / Q000235:genetics; D002213:Capsid / Q000235:genetics / Q000276:immunology*; D036022:Capsid Proteins; D002417:Cattle; D002460:Cell Line; D051379:Mice; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000235:genetics / Q000276:immunology*; D011991:Receptors, Virus / Q000276:immunology; D012401:Rotavirus / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D012400:Rotavirus Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D014357:Trypsin; D014614:Vaccines, Synthetic / Q000494:pharmacology; D014765:Viral Vaccines / Q000494:pharmacology
D036022:Capsid Proteins; D010446:Peptide Fragments; D011991:Receptors, Virus; C060339:VP4 protein, Rotavirus; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; D014357:Trypsin